{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:28:57Z","timestamp":1789810137530,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,31]],"date-time":"2011-12-31T00:00:00Z","timestamp":1325289600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s11914-011-0086-8","type":"journal-article","created":{"date-parts":[[2011,12,30]],"date-time":"2011-12-30T01:37:55Z","timestamp":1325209075000},"page":"93-100","source":"Crossref","is-referenced-by-count":35,"title":["Potential Role for Therapies Targeting DKK1, LRP5, and Serotonin in the Treatment of Osteoporosis"],"prefix":"10.1007","volume":"10","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,31]]},"reference":[{"key":"86_CR1","doi-asserted-by":"crossref","unstructured":"Rachner TD, Khosla S, Hofbauer LC: Osteoporosis: now and the future 2011, 377:1276\u20131287.","DOI":"10.1016\/S0140-6736(10)62349-5"},{"key":"86_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","volume":"341","author":"JJ Westendorf","year":"2004","unstructured":"Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004;341:19\u201339.","journal-title":"Gene"},{"key":"86_CR3","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","volume":"148","author":"R Baron","year":"2007","unstructured":"Baron R, Rawadi G. Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635\u201343.","journal-title":"Endocrinology"},{"key":"86_CR4","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/jbmr.462","volume":"26","author":"D Goltzman","year":"2011","unstructured":"\u2022\u2022 Goltzman D: LRP5, serotonin, and bone: complexity, contradictions, and conundrums. J Bone Miner Res 2011, 26:1997\u20132001. This succinct commentary clearly delineates the current controversies regarding the roles of LRP5 and serotonin in bone mass regulation.","journal-title":"J Bone Miner Res"},{"key":"86_CR5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/34848","volume":"391","author":"A Glinka","year":"1998","unstructured":"Glinka A, Wu W, Delius H, et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391:357\u201362.","journal-title":"Nature"},{"key":"86_CR6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbrc.2004.04.025","volume":"318","author":"K Ohnaka","year":"2004","unstructured":"Ohnaka K, Taniguchi H, Kawate H, et al. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid\u2013induced osteoporosis. Biochem Biophys Res Commun. 2004;318:259\u201364.","journal-title":"Biochem Biophys Res Commun"},{"key":"86_CR7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2474-11-210","volume":"11","author":"JS Butler","year":"2010","unstructured":"Butler JS, Queally JM, Devitt BM, et al. Silencing DKK1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC Musculoskelet Disord. 2010;11:210.","journal-title":"BMC Musculoskelet Disord"},{"key":"86_CR8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","volume":"39","author":"J Li","year":"2006","unstructured":"Li J, Sarosi I, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39:754\u201366.","journal-title":"Bone"},{"key":"86_CR9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","volume":"21","author":"F Morvan","year":"2006","unstructured":"Morvan F, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21:934\u201345.","journal-title":"J Bone Miner Res"},{"key":"86_CR10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bone.2009.11.007","volume":"46","author":"S Reppe","year":"2010","unstructured":"Reppe S, Refvem H, Gautvik VT, et al. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. Bone. 2010;46:604\u201312.","journal-title":"Bone"},{"key":"86_CR11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/jor.21260","volume":"29","author":"JS Butler","year":"2011","unstructured":"\u2022 Butler JS, Murray DW, Hurson CJ, et al.: The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J Orthop Res 2011, 29:414\u2013418. Although not demonstrating causality, this study shows that serum DKK1 levels are higher in subjects with osteoporosis, and inversely associated with BMD at the hip and spine.","journal-title":"J Orthop Res"},{"key":"86_CR12","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2010-2552","volume":"96","author":"D Gatti","year":"2011","unstructured":"Gatti D, Viapiana O, Idolazzi L, et al. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab. 2011;96:1555\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"86_CR13","doi-asserted-by":"crossref","unstructured":"Ng AC, Khosla S, Charatcharoenwitthaya N, et al.: Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1\u00e1 levels in patients with MGUS. Blood. 2011;118:6529\u201334.","DOI":"10.1182\/blood-2011-04-351437"},{"key":"86_CR14","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483\u201394.","journal-title":"N Engl J Med"},{"key":"86_CR15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","volume":"80","author":"M Kaiser","year":"2008","unstructured":"Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol. 2008;80:490\u20134.","journal-title":"Eur J Haematol"},{"key":"86_CR16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156\u201363.","journal-title":"Nat Med"},{"key":"86_CR17","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","volume":"109","author":"S Yaccoby","year":"2007","unstructured":"Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106\u201311.","journal-title":"Blood"},{"key":"86_CR18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","volume":"24","author":"DJ Heath","year":"2009","unstructured":"Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24:425\u201336.","journal-title":"J Bone Miner Res"},{"key":"86_CR19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114:371\u20139.","journal-title":"Blood"},{"key":"86_CR20","doi-asserted-by":"crossref","first-page":"40135","DOI":"10.1074\/jbc.M110.166892","volume":"285","author":"H Glantschnig","year":"2010","unstructured":"Glantschnig H, Hampton RA, Lu P, et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem. 2010;285:40135\u201347.","journal-title":"J Biol Chem"},{"key":"86_CR21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/jpet.111.181404","volume":"338","author":"H Glantschnig","year":"2011","unstructured":"\u2022 Glantschnig H, Scott K, Hampton R, et al.: A rate-limiting role for dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther 2011, 338:568\u2013578. In this study, a fully humanized monoclonal antibody against DKK1 increased bone formation markers and BMD in adult oviarectomized monkeys.","journal-title":"J Pharmacol Exp Ther"},{"key":"86_CR22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14728220902841961","volume":"13","author":"LH Hoeppner","year":"2009","unstructured":"Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009;13:485\u201396.","journal-title":"Expert Opin Ther Targets"},{"key":"86_CR23","first-page":"1","volume":"1653","author":"RH Giles","year":"2003","unstructured":"Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653:1\u201324.","journal-title":"Biochim Biophys Acta"},{"key":"86_CR24","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1210\/jc.2009-2677","volume":"95","author":"E Canalis","year":"2010","unstructured":"Canalis E. Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab. 2010;95:1496\u2013504.","journal-title":"J Clin Endocrinol Metab"},{"key":"86_CR25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","volume":"107","author":"Y Gong","year":"2001","unstructured":"Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513\u201323.","journal-title":"Cell"},{"key":"86_CR26","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","volume":"346","author":"LM Boyden","year":"2002","unstructured":"Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346:1513\u201321.","journal-title":"N Engl J Med"},{"key":"86_CR27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","volume":"70","author":"RD Little","year":"2002","unstructured":"Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70:11\u20139.","journal-title":"Am J Hum Genet"},{"key":"86_CR28","first-page":"741","volume":"77","author":"M Ai","year":"2005","unstructured":"Ai M, Heeger S, Bartels CF, Schelling DK. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Cell. 2005;77:741\u201353.","journal-title":"Cell"},{"key":"86_CR29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1083\/jcb.200201089","volume":"157","author":"M Kato","year":"2002","unstructured":"Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002;157:303\u201314.","journal-title":"J Cell Biol"},{"key":"86_CR30","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1359\/jbmr.2003.18.6.960","volume":"18","author":"P Babij","year":"2003","unstructured":"Babij P, Zhao W, Small C, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res. 2003;18:960\u201374.","journal-title":"J Bone Miner Res"},{"key":"86_CR31","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1128\/MCB.25.12.4946-4955.2005","volume":"25","author":"M Ai","year":"2005","unstructured":"Ai M, Holmen SL, Van Hul W, et al. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol. 2005;25:4946\u201355.","journal-title":"Mol Cell Biol"},{"key":"86_CR32","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nm.2388","volume":"17","author":"Y Cui","year":"2011","unstructured":"\u2022\u2022 Cui Y, Niziolek PJ, MacDonald BT, et al.: Lrp5 functions in bone to regulate bone mass. Nat Med 2011, 17:684\u2013691. Using both genetic and pharmacologic approaches, this study elegantly refutes the role of extraskeletal LRP5 and duodenal-derived serotonin as integral regulators of bone mass.","journal-title":"Nat Med"},{"key":"86_CR33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass 2nd","year":"2005","unstructured":"Glass 2nd DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751\u201364.","journal-title":"Dev Cell"},{"key":"86_CR34","doi-asserted-by":"crossref","first-page":"21162","DOI":"10.1074\/jbc.M501900200","volume":"280","author":"SL Holmen","year":"2005","unstructured":"Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005;280:21162\u20138.","journal-title":"J Biol Chem"},{"key":"86_CR35","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1128\/MCB.01428-09","volume":"30","author":"I Kramer","year":"2010","unstructured":"Kramer I, Halleux C, Keller H, et al. Osteocyte Wnt\/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010;30:3071\u201385.","journal-title":"Mol Cell Biol"},{"key":"86_CR36","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1359\/jbmr.080512","volume":"23","author":"T Kubota","year":"2008","unstructured":"Kubota T, Michigami T, Sakaguchi N, et al. Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd. J Bone Miner Res. 2008;23:1661\u201371.","journal-title":"J Bone Miner Res"},{"key":"86_CR37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2008.09.059","volume":"135","author":"VK Yadav","year":"2008","unstructured":"\u2022\u2022 Yadav VK, Ryu JH, Suda N, et al.: Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825\u2013837. In this study, LRP5 within enterochromaffin cells of the duodenum is shown to regulate Tph1 activity to modulate circulating serotonin levels and thereby control osteoblast-mediated bone formation.","journal-title":"Cell"},{"key":"86_CR38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.1078197","volume":"299","author":"DJ Walther","year":"2003","unstructured":"Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003;299:76.","journal-title":"Science"},{"key":"86_CR39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1083\/jcb.201006123","volume":"191","author":"P Ducy","year":"2010","unstructured":"Ducy P, Karsenty G. The two faces of serotonin in bone biology. J Cell Biol. 2010;191:7\u201313.","journal-title":"J Cell Biol"},{"key":"86_CR40","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/jbmr.44","volume":"25","author":"M Frost","year":"2010","unstructured":"Frost M, Andersen TE, Yadav VK, et al. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J Bone Miner Res. 2010;25:673\u20135.","journal-title":"J Bone Miner Res"},{"key":"86_CR41","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/jbmr.376","volume":"26","author":"M Frost","year":"2011","unstructured":"Frost M, Andersen T, Gossiel F, et al. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J Bone Miner Res. 2011;26:1721\u20138.","journal-title":"J Bone Miner Res"},{"key":"86_CR42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1359\/jbmr.090721","volume":"25","author":"UI Modder","year":"2010","unstructured":"Modder UI, Achenbach SJ, Amin S, et al. Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res. 2010;25:415\u201322.","journal-title":"J Bone Miner Res"},{"key":"86_CR43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-med-090710-133426","volume":"62","author":"G Karsenty","year":"2011","unstructured":"Karsenty G, Yadav VK. Regulation of bone mass by serotonin: molecular biology and therapeutic implications. Annu Rev Med. 2011;62:323\u201331.","journal-title":"Annu Rev Med"},{"key":"86_CR44","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cell.2009.06.051","volume":"138","author":"VK Yadav","year":"2009","unstructured":"Yadav VK, Oury F, Suda N, et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009;138:976\u201389.","journal-title":"Cell"},{"key":"86_CR45","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nm.2098","volume":"16","author":"VK Yadav","year":"2010","unstructured":"Yadav VK, Balaji S, Suresh PS, et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010;16:308\u201312.","journal-title":"Nat Med"},{"key":"86_CR46","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1002\/jbmr.439","volume":"26","author":"H Inose","year":"2011","unstructured":"\u2022 Inose H, Zhou B, Yadav VK, et al.: Efficacy of serotonin inhibition in mouse models of bone loss. J Bone Miner Res 2011, 26: 2002\u20132011. This proof-of-concept study demonstrates that use of a small molecule Tph1 inhibitor to decrease duodenal serotonin synthesis can both prevent and treat oviarectomy-induced bone loss in rodents, and is synergistic when provided in conjunction with bisphosphonate therapy.","journal-title":"J Bone Miner Res"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-011-0086-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-011-0086-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-011-0086-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T16:39:46Z","timestamp":1561135186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-011-0086-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,31]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["86"],"URL":"https:\/\/doi.org\/10.1007\/s11914-011-0086-8","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,31]]}}}